Evaluation of progression-free survival as a surrogate endpoint for overall survival in small cell lung cancer: a systematic review.

ABSTRACT:

Background

Patients with small cell lung cancer (SCLC) face a poor prognosis and have limited treatment options, which has prompted the initiation of clinical trials. Overall survival (OS) is the gold-standard endpoint in clinical trials, reflects the benefits patients derive from interventions. Nevertheless, utilizing OS as an endpoint in clinical trials requires large sample sizes and greater financial supports than using progression-free survival (PFS). This study aims to evaluate whether PFS can serve as a surrogate endpoint for OS, thereby conserving human and financial resources in SCLC clinical trials.

Methods

We conducted a systematic review of randomized controlled trials (RCTs) from online databases (PubMed, EMBASE, and the Cochrane Central Library) and internation

SUBMITTER: Lin G 

PROVIDER: S-EPMC12557674 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature